Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antihypertensive Drugs: Thiazide-Class Diuretics01:15

Antihypertensive Drugs: Thiazide-Class Diuretics

Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Malaria01:29

Malaria

Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Costs and benefits of whole-exome, whole-transcriptome sequencing versus 50-gene panels for genomic profiling in solid tumors.

Journal of medical economics·2026
Same author

Optimizing Drug Discovery in Resource-Limited Settings: Multi-Parameter Optimization and Data-Driven Workflows.

ACS medicinal chemistry letters·2026
Same author

Structure-Activity Relationship of Antischistosomal Aryl Hydantoin (AR102).

Journal of medicinal chemistry·2025
Same author

Screening of Medicines for Malaria Venture Open Boxes Identifies Potent SARS-CoV‑2 Papain-like Protease (PL<sup>pro</sup>) Inhibitors.

ACS omega·2025
Same author

Identifying a next-generation antimalarial trioxolane in a landscape of artemisinin partial resistance.

Science advances·2025
Same author

Characterizing the quick-killing mechanism of action of azithromycin analogs against malaria parasites.

Antimicrobial agents and chemotherapy·2025

Related Experiment Video

Updated: May 28, 2026

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds
07:14

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds

Published on: July 11, 2025

Novel orally active antimalarial thiazoles.

Diego González Cabrera1, Frederic Douelle, Tzu-Shean Feng

  • 1Department of Chemistry, University of Cape Town , Rondebosch 7701, South Africa.

Journal of Medicinal Chemistry
|October 5, 2011
PubMed
Summary

A novel aminomethylthiazole pyrazole carboxamide, compound 3, demonstrates potent antiplasmodial activity against malaria parasites and efficacy in vivo. Further studies confirmed its pharmacokinetic profile and identified potential safety liabilities for drug development.

More Related Videos

Standard Membrane Feeding Assay for the Detection of Plasmodium falciparum Infection in Anopheles Mosquito Vectors
05:28

Standard Membrane Feeding Assay for the Detection of Plasmodium falciparum Infection in Anopheles Mosquito Vectors

Published on: May 12, 2022

Related Experiment Videos

Last Updated: May 28, 2026

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds
07:14

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds

Published on: July 11, 2025

Standard Membrane Feeding Assay for the Detection of Plasmodium falciparum Infection in Anopheles Mosquito Vectors
05:28

Standard Membrane Feeding Assay for the Detection of Plasmodium falciparum Infection in Anopheles Mosquito Vectors

Published on: May 12, 2022

Area of Science:

  • Medicinal Chemistry
  • Drug Discovery
  • Parasitology

Background:

  • Malaria remains a significant global health burden, necessitating the development of new antimalarial drugs.
  • Drug resistance in Plasmodium falciparum parasites poses a major challenge to existing therapies.

Purpose of the Study:

  • To identify novel antimalarial lead compounds with potent activity and favorable drug-like properties.
  • To evaluate the in vitro and in vivo efficacy, pharmacokinetics, and preliminary toxicity of a promising lead compound.

Main Methods:

  • Whole-cell screening of a SoftFocus kinase library identified lead compound 3.
  • In vitro antiplasmodial activity was assessed against chloroquine-sensitive (NF54) and resistant (K1) Plasmodium falciparum strains.
  • In vivo efficacy was evaluated in the Plasmodium berghei mouse model.
  • Pharmacokinetic studies were conducted in rats following oral and intravenous administration.
  • In vitro cytotoxicity and CYP450 inhibition assays were performed.

Main Results:

  • Compound 3 exhibited potent in vitro antiplasmodial activity (IC50 values of 0.07-0.08 μM) and good microsomal metabolic stability.
  • In vivo, compound 3 demonstrated significant efficacy (99.5% activity, 9 days survival) in the P. berghei mouse model.
  • Pharmacokinetic studies showed good oral bioavailability (51%), a moderate half-life (3 h), and a high volume of distribution in rats.
  • Preliminary toxicity profiling indicated moderate inhibition of CYP1A2 and CYP2D6, and a potential hERG liability.

Conclusions:

  • Aminomethylthiazole pyrazole carboxamide lead 3 is a promising antimalarial candidate with potent in vitro and in vivo activity.
  • Compound 3 possesses favorable pharmacokinetic properties, suggesting potential for oral administration.
  • Further optimization is warranted to address identified CYP450 inhibition and hERG liability concerns for safe and effective antimalarial drug development.